AI-Designed Medicines Get a $5 Billion Boost: Isomorphic Labs Raises a Series C, Aiming for Clinical Trials
Updated 7 AM PT (10 AM ET), Tuesday, Nov. 17, 2026. Isomorphic Labs, the Alphabet-backed AI drug-design company spun out of Google DeepMind, says it has raised a $5 billion Series C. In its announcement, the London company says the money will scale its drug design engine and its pipeline of AI-designed candidates, and help it move toward clinical trials. It does not say any of those candidates is in a trial yet.
What Isomorphic announced
- The round: $5 billion, described by the company as oversubscribed and co-led by Greenoaks and Sequoia Capital.
- Who invested: Andreessen Horowitz and several other new investors, “continued significant investment” from Alphabet, and all existing investors: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.
- The technology: The company’s drug design engine, IsoDDE, which it says unifies foundational simulation AI models that work across multiple therapeutic areas and drug modalities.
- Early results: Isomorphic says the momentum is “yielding positive preclinical results” for internal programs in oncology and immunology and with partners, “setting the stage for clinical entry.”
- What the money funds: Maturing IsoDDE, expanding into new biology, building a partner ecosystem, and building AI-first translational and clinical development infrastructure as it advances candidates to clinical trials.
What the company and investors say
CEO Sir Demis Hassabis said the round lets the company accelerate “driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients.” Greenoaks founder Neil Mehta called drug discovery “an optimization challenge of almost infinite scale.” These are statements from the company’s release, not independent assessments.
What isn’t known
The release gives no valuation and names no drug candidates, targets or trial dates. TechCrunch reports the company has deals with Eli Lilly, Novartis and Johnson & Johnson and that the round follows a $2.1 billion Series B in May, and notes that Bloomberg earlier reported talks at a $50 billion valuation. Neither figure comes from Isomorphic’s own announcement. “Positive preclinical results” is the company’s description; no data accompanied it.
PCGeek’s take
A $5 billion round is a strong vote of confidence in AI-designed medicines, with Alphabet still in the cap table and two of the biggest names in venture co-leading. The real test is the one the release says is next: whether these candidates make it into people and work there. Drug development is slow and most candidates fail, so treat this as funding for a plan, not proof of a cure. We will cover the first clinical-trial news when Isomorphic announces it.
Image: Isomorphic Labs, artwork from its Series C announcement. A credit is not a license; the image is used to illustrate the company’s own news.
Would you trust a medicine designed mostly by AI once it clears trials, or does it need more proof first? Tell us in the comments. Follow @pcgeekinfo for updates.